

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

CHANGE OF FINANCIAL CONTROLLER

R e s u m e o f F i n a n c i a l C o n t r o l l e r

and the related information which need to be brought to the attention of the shareholders of the Company. The Stock Exchange of Hong Kong Limited.

A b o u t F i n a n c i a l C o n t r o l l e r

The Board has read and accepted Mr. Chen Jia (Mr. Chen) has been appointed as the Financial Controller of the Company with effect from August 21, 2023. The biographical details of Mr. Chen are as follows:

Mr. Chen, 48, is a qualified financial manager with over 20 years of financial management experience in large, listed public companies. She obtained a bachelor's degree in Economics from Hebei University and received a master's degree in Accounting from Tianjin University. She also holds a license as a Chartered Global Management Accountant and is a member of the Institute of Public Accountants. From 2012 to 2015, he worked at the financial director of IBM Software Technology (Shenzhen) Co., Ltd. and Lenovo Software Technology (Shenzhen) Co., Ltd.; from 2016 to 2017, he worked at the head of financial controller of the head office of the subsidiary of IBM Global Services China; from 2017 to 2022, he was the vice-chairman of SF Energy Group, a public company; from 2022 to 2023, he was the financial controller of SF Alliance; he joined Hepalink in August 2023.

